| Literature DB >> 22862851 |
Samuel R Bozeman1, David C Hoaglin, Tanya M Burton, Chris L Pashos, Rami H Ben-Joseph, Christopher S Hollenbeak.
Abstract
BACKGROUND: Being overweight or obese increases risk for cardiometabolic disorders. Although both body mass index (BMI) and waist circumference (WC) measure the level of overweight and obesity, WC may be more important because of its closer relationship to total body fat. Because WC is typically not assessed in clinical practice, this study sought to develop and verify a model to predict WC from BMI and demographic data, and to use the predicted WC to assess cardiometabolic risk.Entities:
Mesh:
Year: 2012 PMID: 22862851 PMCID: PMC3441760 DOI: 10.1186/1471-2288-12-115
Source DB: PubMed Journal: BMC Med Res Methodol ISSN: 1471-2288 Impact factor: 4.615
Specifications of Cardiometabolic Risk Factor Sets
| | |||||||
| WC | Men ≥ 102 cm | Men ≥ 102 cm | Men ≥ 102 cm | Men ≥ 102 cm | Men ≥ 102 cm | Men ≥ 94 cmb | Men ≥ 94 cmb |
| | Women ≥ 88 cm | Women ≥ 88 cm | Women ≥ 88 cm | Women ≥ 88 cm | Women ≥ 88 cm | Women ≥ 80 cmb | Women ≥ 80 cmb |
| TG | ≥ 150 mg/dL | NA | NA | ≥ 150 mg/dL | ≥ 150 mg/dL | ≥ 150 mg/dL, or | NA |
| | | | | | | on treatment for high TG | |
| HDL | Men < 40 mg/dL | NA | NA | Men < 40 mg/dL | Men < 40 mg/dL | Men < 40 mg/dL | NA |
| | Women < 50 mg/dL | | | Women < 50 mg/dL | Women < 50 mg/dL | Women < 50 mg/dL or | |
| | | | | | | on treatment for low HDL | |
| BP | SBP ≥ 130 mm Hg or | NA | NA | NA | NA | SBP ≥ 130 mm Hg or | NA |
| | DBP ≥ 85 mm Hg or | | | | | DBP ≥ 85 mm Hg or | |
| | current use of anti-hypertensive medication | | | | | current use of anti-hypertensive medication | |
| | | | | | | (Same as for NCEP) | |
| FPG | ≥ 100 mg/dL or | NA | ≥ 126 mg/dL or | NA | ≥ 126 mg/dL or | ≥ 100 mg/dL or | NA |
| use of diabetes medication | use of diabetes medication | use of diabetes medication | previously diagnosed type 2 diabetes | NA |
WC waist circumference, TG triglycerides, HDL high-density lipoprotein, BP blood pressure, FPG fasting plasma glucose, NCEP National Cholesterol Education Program, ATP III Adult Treatment Panel III.
a Ford, E. S. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005, 28:2745–2749.
b For White and African American subjects. Refer to a Ford, E.S. article for other ethnic group-specific thresholds including for Mexican-American subjects.
Characteristics of NHANES 2001–2 sample
| | ||||
| 43.95 | 0.559 | 44.64 | 0.531 | |
| | | | | |
| White | 76.6% | | 76.1% | |
| Black | 10.1% | | 11.1% | |
| Hispanic | 13.3% | | 12.8% | |
| | | | | |
| WC | 97.4 | 0.295 | 90.5 | 0.384 |
| BMI | 27.2 | 0.088 | 26.9 | 0.143 |
| Overweighta | 43.5% | | 30.3% | |
| Obeseb | 23.9% | 28.2% | ||
a BMI ≥ 25.
b BMI ≥ 30.
Models for predicting waist circumference from BMI
| | ||||||
| Constant | 22.61306 | 0.8792 | < 0.0001 | 28.81919 | 0.8011 | < 0.0001 |
| Age | 0.1583812 | 0.0049 | < 0.0001 | - | - | - |
| I {Age ≥ 35} | - | - | - | −3.688953 | 0.8308 | < 0.0001 |
| - | - | - | 0.125975 | 0.0118 | < 0.0001 | |
| BMI | 2.520738 | 0.0338 | < 0.0001 | 2.218007 | 0.0318 | < 0.0001 |
| Black | −3.703501 | 0.3194 | < 0.0001 | −0.6570163 | 0.6730 | 0.344 |
| Hispanic | −1.736731 | 0.4848 | 0.003 | 0.1818819 | 0.6729 | 0.79 |
Figure 1Boxplot of difference (cm) between actual and predicted WC (actual WC minus predicted WC) in NHANES participants age 54 to 69 years.
Characteristics of ARIC sample at Examination 4
| | ||||
|---|---|---|---|---|
| 61 | 4.5 | 61 | 4.5 | |
| | | | | |
| White | 81% | | 75% | |
| Black | 19% | | 25% | |
| Hispanic | 0% | | 0% | |
| | | | | |
| WC (cm) | 103 | 10.7 | 99 | 13.9 |
| Derived BMI (kg/m2) | 28.4 | 4.0 | 28.2 | 5.0 |
| Height (cm) | 176 | 6.5 | 162 | 5.9 |
| Weight (lbs) | 194 | 30.7 | 163 | 30.9 |
| Overweighta | 80% | | 71% | |
| Obeseb | 33% | 35% | ||
a BMI ≥ 25.
b BMI ≥ 30.
Figure 2Boxplot of difference (cm) between actual and predicted WC (actual WC minus predicted WC) in ARIC participants.
Risk Factor Set Membership from Predicted WC in ARIC Women; BMI ≤ 40; Age < 70. (N = 4967)
| NCEP-ATP III Metabolic Syndrome | 50.2% (2495) | 98.1% | 95.4% | 98.2% | 96.8% |
| IDF Metabolic Syndrome | 55.2% (2744) | 98.7% | 98.7% | 98.3% | 98.5% |
| Abdominal Obesity1 (AO1) | 76.4% (3795) | 94.2% | 88.0% | 82.6% | 86.8% |
| AO1 and DM | 13.6% (675) | 98.8% | 95.3% | 99.8% | 99.2% |
| AO1 and Dyslipidemia | 45.2% (2243) | 96.9% | 90.7% | 97.6% | 94.5% |
| AO1, DM and Dyslipidemia | 9.6% (479) | 98.9% | 96.0% | 99.9% | 99.5% |
| Abdominal Obesity 2 | 91.8% (4560) | 95.7% | 97.0% | 51.4% | 93.2% |
NCEP-ATP III National Cholesterol Education Program, Adult Treatment Panel III.
IDF International Diabetes Foundation.
Abdominal Obesity 1: ≥ 88 cm.
Abdominal Obesity 2: ≥ 80 cm.
DM Diabetes Mellitus.
Risk Factor Set Membership from Predicted WC in ARIC Men; BMI ≤ 40; Age < 70. (N = 3806)
| NCEP-ATP III Metabolic Syndrome | 49.8% (1895) | 94.5% | 96.9% | 94.5% | 95.7% |
| IDF Metabolic Syndrome | 58.9% (2242) | 93.8% | 94.1% | 91.1% | 92.9% |
| Abdominal Obesity 1 (AO1) | 48.8% (1857) | 83.9% | 87.4% | 84.0% | 85.7% |
| AO1 and DM | 11.9% (454) | 90.3% | 89.9% | 98.7% | 97.6% |
| AO1 and Dyslipidemia | 33.3% (1266) | 86.0% | 89.0% | 92.8% | 91.5% |
| AO1, DM and Dyslipidemia | 9.2% (352) | 90.3% | 89.8% | 99.0% | 98.2% |
| Abdominal Obesity 2 | 81.2% (3089) | 92.8% | 93.0% | 68.9% | 88.5% |
NCEP-ATP III National Cholesterol Education Program, Adult Treatment Panel III.
IDF International Diabetes Foundation.
Abdominal Obesity 1: ≥ 102 cm.
Abdominal Obesity 2: ≥ 94 cm.
DM Diabetes Mellitus.